REG - AstraZeneca PLC - Director Declaration

AstraZenecaAnnouncement

08/05/2019 11:00

RNS Number : 3675Y
AstraZeneca PLC
08 May 2019
 


8 May 2019 11:00 BST
 
Director Declaration
 
AstraZeneca PLC (the Company) today announced that Geneviève Berger, a Non-Executive Director of the Company, was re-elected as a director of L'Air Liquide S.A. for a term of four years following the conclusion of its Annual General Meeting of Shareholders, with effect from 7 May 2019.
 
This announcement is made pursuant to Listing Rule 9.6.14 R (2).
 
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca.



 
Media Relations












Gonzalo Viña






+44 203 749 5916




Rob Skelding


Oncology


+44 203 749 5821




Rebecca Einhorn


Oncology


+1 301 518 4122




Matt Kent


BioPharma


+44 203 749 5906




Jennifer Hursit


Other


+44 203 749 5762




Christina Malmberg Hägerstrand


Sweden


+46 8 552 53 106




Michele Meixell


US


+1 302 885 2677




















Investor Relations












Thomas Kudsk Larsen






+44 203 749 5712




Henry Wheeler


Oncology


+44 203 749 5797




Christer Gruvris


BioPharma (cardiovascular; metabolism)


+44 203 749 5711




Nick Stone


BioPharma (respiratory, renal)


+44 203 749 5716




Josie Afolabi


Other medicines


+44 203 749 5631




Craig Marks


Finance, fixed income


+44 7881 615 764




Jennifer Kretzmann


Corporate access, retail investors


+44 203 749 5824




US toll-free






+1 866 381 72 77



 
Adrian Kemp
Company Secretary
AstraZeneca PLC
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RDNVVLBBKEFEBBL